|
1）Gasser C, Gautier E, Steck A, et al. Hemolytic-uremic syndrome: bilateral necrosis of the renal cortex in acute acquired hemolytic anemia. Schweiz Med Wochenschr. 1955; 85: 905-9
|
|
|
|
2）Moake JL. Thrombotic microangiopathies. N Engl J Med. 2002; 347: 589-600
|
|
|
|
|
3）Furlan M, Robles R, Galbusera M, et al. von Willebrand factor-cleaving protease in thrombotic thrombocytopenic purpura and the hemolytic-uremic syndrome. N Engl J Med. 1998; 339: 1578-84
|
|
|
|
|
|
4）Tsai HM, Lian EC. Antibodies to von Willebrand factor-cleaving protease in acute thrombotic thrombocytopenic purpura. N Engl J Med. 1998; 339: 1585-94
|
|
|
|
|
|
5）松本雅則．非典型溶血性尿毒症症候群．In: 高久史麿，他編．Annual Review 血液．2011年度版．東京: 中外医学社; 2011. p.174-81
|
|
|
|
|
|
6）George JN, Nester CM. Syndromes of thrombotic microangiopathy. N Engl J Med. 2014; 371: 654-66
|
|
|
|
|
|
7）Scotland SM, Willshaw GA, Smith HR, et al. Properties of strains of Escherichia coli belonging to serogroup O157 with special reference to production of Vero cytotoxins VT1 and VT2. Epidemiol Infect. 1987; 99: 613-24
|
|
|
|
|
|
8）Zoja C, Angioletti S, Donadelli R, et al. Shiga toxin-2 triggers endothelial leukocyte adhesion and transmigration via NF-kappaB dependent up-regulation of IL-8 and MCP-1. Kidney Int. 2002; 62: 846-56
|
|
|
|
|
|
9）Karpman D, Papadopoulou D, Nilsson K, et al. Platelet activation by Shiga toxin and circulatory factors as a pathogenetic mechanism in the hemolytic uremic syndrome. Blood. 2001; 97: 3100-8
|
|
|
|
|
|
10）Lo NC, Turner NA, Cruz MA, et al. Interaction of Shiga toxin with the A-domains and multimers of von Willebrand Factor. J Biol Chem. 2013; 288: 33118-23
|
|
|
|
|
|
11）Aka JA, Jalacic S, Ciol MA, et al. Relative nephroprotection during Escherichia coli O157: H7 infections: Association with intravenous volume expansion. Pediatrics. 2005; 115: e673-80
|
|
|
|
|
|
12）Hickey CA, Beattie TJ, Cowieson J, et al. Early volume expansion during diarrhea and relative nephroprotection during subsequent hemolytic uremic syndrome. Arch Pediatr Adolesc Med. 2011; 165: 884-9
|
|
|
|
|
|
13）上田恭典．血栓性血小板減少性紫斑病と溶血性尿毒症症候群．日本内科学会雑誌．2009; 98: 1627-33
|
|
|
|
|
|
14）Constantinescu AR, Bitzan M, Weiss LS, et al. Non-enteropathic hemolytic uremic syndrome: causes and short-term course. Am J Kidney Dis. 2004; 43: 976-82
|
|
|
|
|
|
15）Ohanian M, Cable C, Halka K. Eculizumab safely reverses neurologic impairment and eliminates need for dialysis in severe atypical hemolytic uremic syndrome. Clin Pharmacol. 2011; 3: 5-12
|
|
|
|
|
|
16）Sullivan M, Erlic Z, Hoffmann MM, et al. Epidemiological approach to identifying genetic predispositions for atypical hemolytic uremic syndrome. Ann Hum Genet. 2010; 74: 17-26
|
|
|
|
|
|
17）Stühlinger W, Kourilsky O, Kanfer A, et al. Letter: Haemolytic-uraemic syndrome: evidence for intravascular C3 activation. Lancet. 1974; 2: 788-9
|
|
|
|
|
|
18）Jozsi M, Licht C, Strobel S, et al. Factor H autoantibodies in atypical hemolytic uremic syndrome correlate with CFHR1/CFHR3 deficiency. Blood. 2008; 111: 1512-4
|
|
|
|
|
|
19）Goicoechea de Jorge E, Harris CL, Esparza-Gordillo J, et al. Gain-of-function mutations in complement factor B are associated with atypical hemolytic uremic syndrome. Proc Natl Acad Sci USA. 2007; 104: 240-5
|
|
|
|
|
|
20）Fremeaux-Bacchi V, Miller EC, Liszewski MK, et al. Mutations in complement C3 predispose to development of atypical hemolytic uremic syndrome. Blood. 2008; 112: 4948-52
|
|
|
|
|
|
21）Jodele S, Licht C, Goebel J, et al. Abnormalities in the alternative pathway of complement in children with hematopoietic stem cell transplant-associated thrombotic microangiopathy. Blood. 2013; 122: 2003-7
|
|
|
|
|
|
22）Loirat C, Frémeaux-Bacchi V. Atypical hemolytic uremic syndrome. Orphanet J Rare Dis. 2011; 6: 60
|
|
|
|
|
|
23）Mele C, Remuzzi G, Noris M. Hemolytic uremic syndrome. Semin Immunopathol. 2014; 36: 399-420
|
|
|
|
|
|
24）Lemaire M, Fremeaux-Bacchi V, Schaefer F, et al. Recessive mutations in DGKE cause atypical hemolytic-uremic syndrome. Nat Genet. 2013; 45: 531-6
|
|
|
|
|
|
25）Sawai T, Nangaku M, Ashida A, et al. Diagnostic criteria for atypical hemolytic uremic syndrome proposed by the Joint Committee of the Japanese Society of Nephrology and the Japan Pediatric Society. Pediatr Int. 2014; 56: 1-5
|
|
|
|
|
26）Feng S, Eyler SJ, Zhang Y, et al. Partial ADAMTS13 deficiency in atypical hemolytic uremic syndrome. Blood. 2013; 122: 1487-93
|
|
|
|
|
|
27）吉田瑶子，藤村吉博．非典型溶血性尿毒症症候群(aHUS)の病態と治療戦略．血液内科．2014(印刷中)
|
|
|
|
|
|
28）Ariceta G, Besbas N, Johnson S, et al. Guidelines for the investigation and initial therapy of diarrhea-negative hemolytic uremic syndrome. Pediatr Nephrol. 2009; 24: 687-96
|
|
|
|
|
|
29）Dragon-Durey MA, Sethi SK, Bagga A, et al. Clinical features of anti-factor H autoantibody-associated hemolytic uremic syndrome. J Am Soc Nephrol. 2010; 21: 2180-7
|
|
|
|
|
|
30）Gruppo RA, Rother RP. Eculizumab for congenital atypical hemolytic-uremic syndrome. N Engl J Med. 2009; 360: 544-6
|
|
|
|
|
|
31）Nurnberger J, Philipp T, Witzke O, et al. Eculizumab for atypical hemolytic-uremic syndrome. N Engl J Med. 2009; 360: 542-4
|
|
|
|
|
|
32）Legendre CM, Licht C, Muus P, et al. Terminal complement inhibitor eculizumab in atypical hemolytic-uremic syndrome. N Engl J Med. 2013; 368: 2169-81
|
|
|
|
|
|
33）Zuber J, Le Quintrec M, Krid S, et al. Eculizumab for atypical hemolytic uremic syndrome recurrence in renal transplantation. Am J Transplant. 2012; 12: 3337-54
|
|
|
|
|
|
34）Jodele S, Fukuda T, Vinks A, et al. Eculizumab therapy in children with severe hematopoietic stem cell transplantation-associated thrombotic microangiopathy. Biol Blood Marrow Transplant. 2014; 20: 518-25
|
|
|
|
|